Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia

Launched by YONGQUAN SHI · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called Weifuchun tablet for treating a condition known as gastric intestinal metaplasia in adults who do not have a Helicobacter pylori infection. Gastric intestinal metaplasia is a change in the stomach lining that can sometimes lead to more serious problems. The researchers want to find out if Weifuchun can help reduce this condition and how it compares to folic acid, a vitamin that is also being tested.

To participate in this trial, you need to be between 18 and 75 years old and have a specific diagnosis confirmed by a recent endoscopy. It’s important that you do not have an active Helicobacter pylori infection. Over a period of six months, participants will take either Weifuchun tablets or folic acid daily and visit the clinic every four weeks for check-ups and tests. This trial is not yet recruiting participants, but it aims to help find better treatments for gastric intestinal metaplasia, which could be important for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients aged from 18 to 75 years old.
• • patients with OLGIM stage Ⅱ-Ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months.
• • patients without Helicobacter pylori infection, including patients who had successful Helicobacter pylori eradication before enrollment.
• Exclusion Criteria:
• • a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and/or statins.
• • a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor.
• • a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study.
• • breastfeeding or pregnancy.
• • a history of substance abuse or alcohol abuse within the past one year.
• • patients with severe mental illness.
• • refusal to undergo drug treatment.
• • refusal to sign informed consent.